Browsing Tag
National Stock Exchange of India Limited
37 posts
Nibe Limited opens Shirdi defence complex as Suryastra rocket system puts NIBE stock in focus
Nibe Limited’s Shirdi defence complex and Suryastra rocket system put NIBE stock in focus. Find out what this means for India’s defence sector.
Belrise Industries FY26 results: Why is BELRISE stock in focus after strong earnings and aerospace expansion?
Belrise is growing beyond auto parts while its stock trades near highs. Can FY26 earnings and aerospace deals justify the next leg?
Allied Digital Services FY26 revenue hits record Rs 968cr as #ADSL eyes AI-led expansion
Allied Digital Services reported record FY26 revenue and a dividend, but margins and debtor days raise questions. Read the full analysis.
Universal Cables FY2026 profit jumps as UNIVCABLES bets on EHV cables, exports and Satna modernisation
Universal Cables is growing fast, but capex, debt and export execution now decide the next leg. Read the full FY2026 analysis.
Anupam Rasayan to acquire up to 48.2% stake in Bliss GVS Pharma as #ANURAS expands pharma value-chain bet
Anupam Rasayan is moving beyond chemistry into formulations. Can the Bliss GVS Pharma deal justify the market’s high expectations?
EPACK Prefab (EPACKPEB) rebounds after FY26 earnings, but can prefab capacity expansion sustain investor confidence?
EPACKPEB has growth, cash and orders. The bigger test is whether prefab capacity can turn India’s speed problem into durable earnings.
Samvardhana Motherson expands Abu Dhabi manufacturing bet as MOTHERSON trades near 52-week high
Motherson’s Abu Dhabi hub is more than capacity expansion. It signals how Gulf industrial policy is courting Indian manufacturing scale.
Gallantt Ispat (NSE: GALLANTT) FY26 results: Can its margin-led steel growth story survive the next expansion test?
Gallantt Ispat beat steel pricing pressure with margins intact. Now its ₹3,000 crore capex must prove the rally has legs.
Zen Technologies (NSE: ZENTEC) stock faces FY27 execution test after muted FY26 and Rs 1,336cr order book
Zen Technologies had a weak FY26. A ₹1,336 crore defence order book now decides whether FY27 restores investor confidence.
Gujarat Themis Biosyn (GUJTHEM) bets on global branded generics with €158m Sanofi portfolio deal
Find out how Gujarat Themis Biosyn’s €158m Sanofi portfolio deal could reshape its global anti-infective growth strategy.